Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > Janssen Submits IV Simponi For Moderate to Severe RA

Washington Drug Letter

Sept. 24, 2012 | Vol. 44 No. 38

Janssen Submits IV Simponi For Moderate to Severe RA

Janssen Biotech has submitted a BLA seeking approval of an IV formulation of Simponi to treat adults with moderate to severe rheumatoid arthritis (RA).

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Mylan Launches Generic Tricor Tablets Is the FDA Approving too Many Drugs Starting with X and Z?Court Rejects Merck Deal Over Vioxx Citizens in Poor EU States Can’t Afford Medicines, Health Promoters Say

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.